Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Net Income (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Net Income data on record, last reported at -$7.9 million in Q3 2025.

  • For Q3 2025, Net Income rose 37.79% year-over-year to -$7.9 million; the TTM value through Sep 2025 reached -$47.6 million, up 13.33%, while the annual FY2024 figure was -$56.6 million, 16.64% up from the prior year.
  • Net Income reached -$7.9 million in Q3 2025 per RANI's latest filing, up from -$11.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$5.5 million in Q2 2021 and bottomed at -$28.7 million in Q3 2021.
  • Average Net Income over 5 years is -$14.4 million, with a median of -$14.1 million recorded in 2023.
  • Peak YoY movement for Net Income: crashed 895.84% in 2021, then soared 42.78% in 2022.
  • A 5-year view of Net Income shows it stood at -$13.3 million in 2021, then dropped by 28.74% to -$17.1 million in 2022, then grew by 17.95% to -$14.1 million in 2023, then decreased by 11.85% to -$15.7 million in 2024, then skyrocketed by 49.66% to -$7.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$7.9 million in Q3 2025, -$11.2 million in Q2 2025, and -$12.7 million in Q1 2025.